Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.74 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.74 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | GUSB | P08236 | 2/20 | 0.52 |
| ▸ | EBP | Q15125 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11571902 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL16026570 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL8575694 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL18630767 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL6057505 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL11569527 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL4307534 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL8536145 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL18631049 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL3814492 | 1.00 | GNAI3 (0.74) | GNAI3GNAO1GNAI1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | claimed |
| CN-1270524-A | Cationic polymers as toxin binders | GELTEX PHARMA INC (US) | 2000-10-18 | — | — | CN | claimed |
| EP-1014999-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | claimed |
| US-6007803-A | ADMINISTERING TO MAMMAL A CATIONIC POLYMER TO INHIBIT PATHOGENIC TOXINS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | claimed |
| WO-1999015186-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | claimed |
| CN-104428331-B | Active energy beam polymer resin composition and the laminated body for using the resin combination | 东洋油墨SC控股株式会社 | 2019-02-15 | — | — | CN | disclosed |
| CN-104428331-A | Active energy ray-polymerizable resin composition and laminate obtained using resin composition | TOYO INK SC HOLDINGS CO LTD | 2015-03-18 | — | — | CN | disclosed |
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6692732-B2 | Administering cationic polymers to mammals to prevent poisons or antigens from microorganisms such as bacteria, viruses, fungi or parasites; deactivation | GENZYME CORPORATION | 2004-02-17 | — | — | US | disclosed |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-1999015186-A1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5834407-A | ANTIWEAR AND EXTREME PRESSURE OIL ADDITIVE COMPRISING HYDROCARBYL SUBSTITUTED-2-(THIO OR OXO)-1,3-DITHIOLANE, OXATHIOLANE OR THIAZOLIDINES AS SUBSTITUTE FOR ZINC DIALKYL DITHIOPHOSPHATE | THE LUBRIZOL CORPORATION (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0825246-A2 | Lubricants and functional fluids containing heterocyclic compounds | The Lubrizol Corporation (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0825247-A2 | Compositions containing thiocarbonates and acylated-nitrogen containing compounds | The Lubrizol Corporation (US) | 1998-02-25 | — | — | EP | disclosed |
| US-4173580-A | Production of β-haloalkylaminosulfonyl halides | BASF AKTIENGESELLSCHAFT (DE) | 1979-11-06 | — | — | US | disclosed |
| US-4093615-A | Cyclic oligomers of N-substituted aziridines | THE DOW CHEMICAL COMPANY (US) | 1978-06-06 | — | — | US | disclosed |
| US-4014931-A | FROM AZIRIDINE AND SULFURYL HALIDE | BASF AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
| US-3935269-A | Copolymers of N-substituted aziridines and epoxides episulfides | THE DOW CHEMICAL COMPANY (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | PIGS, ANTXR2, MSN | GNAI3 959/4885GNAO1 1161/4885GNAI1 915/4885 |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | PIGS, ANTXR2, MSN | GNAI3 959/4885GNAO1 1161/4885GNAI1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.